ArsenalBio
@ArsenalBio
Followers
2K
Following
11
Media
170
Statuses
192
We’re a programmable clinical-stage cell therapy company focused on the realization of solid tumor cell therapies. Our purpose is very clear: defeat cancer.
Joined October 2019
Thanks to @BiotechTV and @bradloncar for sitting down with our CEO, @KDrazan , M.D., to hear about the latest on our CAR T cell therapies specifically designed to overcome the challenges presented by solid tumors. Full video available here: #CancerResearch.
𝐂𝐀𝐑-𝐓 𝐋𝐨𝐠𝐢𝐜-𝐆𝐚𝐭𝐢𝐧𝐠: @ArsenalBio CEO @KDrazan describes the idea of logic-gating, which might allow CAR-T therapies to work in solid tumors when targeting more than one antigen is needed. Full interview:
1
0
7
We’re honored to have @KDrazan, MD, Co-founder, CEO, and Chairman of the Board, recognized as a winner in the EY Entrepreneur Of The Year® 2025 Bay Area program. #EOYUS #EOYBAYAREA
0
2
6
Heading to Fully Connected 2025? Hear from ArsenalBio’s Sofia Panagiotopoulou as she presents “A T-cell foundation model for AI-powered target discovery and precision medicine” on June 18. Learn more and view the full agenda:
0
2
8
We’re proud to share that @KDrazan, MD, ArsenalBio’s Co-founder, CEO, and Chairman, has been recognized along with other inspiring business leaders as a finalist in the EY Entrepreneur Of The Year® 2025 Bay Area program. Learn more: #EOYUS #EOYBAYAREA
0
1
4
Future scientists at work! Each year at ArsenalBio, we hold a Bring a Kid to Work Day, where young minds explore our labs and experience the wonders of #STEM. #BringYourKidToWorkDay #TakeYourChildToWorkDay
0
0
0
Our One Team value extends to our local community by helping our neighbors with a cleanup day. Happy Earth Day.
0
0
1
Next week at the @AACR Annual Meeting, we’ll share research on how our synthetic pathway activator (SPA) modules enhance the functional persistence of our CAR T cell therapies and prevent T cell exhaustion. #AACR25 #CancerResearch
0
0
1
ArsenalBio CSO @nickhaining recently spoke with @DrugDiscovNews about our multi-pronged approach of equipping T cells to defeat solid tumors. Check out the article, "Armoring up CAR T cells to fight solid tumors" at #CancerResearch #CellTherapy
0
3
8
It’s a busy week for ArsenalBio as we present at three scientific conferences: Supply Chain & Logistics for Cell & Gene Therapies Summit, Cell Therapy Potency Assay Summit, and SITC Spring Scientific Cellular Therapy for Solid Tumors. Details on the image.
0
2
4
Happy #EmployeeAppreciationDay to our 270 employees! We're so grateful for you and your many contributions toward our collective mission of defeating cancer. #CancerResearch #Biotech
0
1
4
This Kidney Cancer Awareness Month, we reaffirm our commitment to developing cell therapies to defeat solid tumors such as kidney cancer. We are currently in a Phase 1/2 clinical study of AB-2100, our CAR T cell therapy for the potential treatment of clear-cell renal cell
0
0
1
Proud moment: ArsenalBio is officially @GPTW_US Certified. This recognition highlights our inclusive, innovative culture where people thrive and make an impact. More here: #GreatPlaceToWork #GPTWCertified
0
2
4
We are proud to celebrate International Day of Women and Girls in Science and the dedicated and talented women professionals at ArsenalBio. #WomeninScience #WomeninSTEM
0
1
6
On World Cancer Day and EVERY day, we're committed to defeating solid tumor cancers. Solid tumors account for 90% of all cancers. At Arsenal, we're developing cell therapies to address the large unmet need that remains in multiple types of solid tumors. Our programmable
0
1
5
We're heading to the 9th Annual Tumor Models SF Summit this week. Thanks to ArsenalBio scientist Suchismita Mohanty, PhD, for presenting and serving as chair of the Drug Discovery & Screening track. Also, don't miss Alma Gomez's poster on preclinical research on AB-2100, our CAR
0
0
2
Our greatest asset at ArsenalBio is our people. We’re thrilled to recognize our 2024 Mission Award recipients, Randy Reyes, JD, Corporate Counsel II, and Michelle Tan, Senior Scientist I. More on our team & open positions: #CancerResearch
0
0
2
Press Release: @bmsnews has exercised its exclusive license option for our AB-4000 series, advancing our collaboration to develop next-gen T cell therapies for solid tumors. Learn more: #CellTherapy #Biotech #CancerResearch
0
0
4
CEO @KDrazan, MD, will moderate a panel of R&D experts tomorrow (Jan. 11) at the @LongwoodLeaders #SanFranciscoCEO forum. The panel will discuss the latest insights and strategies for R&D collaboration. #JPM25 #CellTherapy
0
1
3